Antidepressants' benefits exceed risks: study

By Julie Steenhuysen

CHICAGO (Reuters) - The benefits of antidepressants for children and teens far outweigh the risk of suicide, and U.S. regulators should revise strong warnings that may have scared off some doctors and patients, researchers said on Tuesday.

A wide-reaching review of studies on antidepressants in young patients showed the risk of suicidal behavior is smaller than previously thought and should be viewed in light of the relief these drugs can offer, the researchers said.

"The benefits seem to be much stronger than the risks," said Dr. David Brent, a researcher at the University of Pittsburgh School of Medicine, whose study appeared in the Journal of the American Medical Association.

The research calls into question "black box" warnings on the labels of antidepressants called selective serotonin reuptake inhibitors or SSRIs that caution of a higher risk of suicidal behavior among children and teen-agers.

The U.S. Food and Drug Administration said there is no reason for a change in the labeling and said doctors are still free to prescribe the drugs to young patients.

The FDA introduced the warnings on the most popular antidepressants in October 2004 after studies in the United States and Britain suggested the drugs may raise the risk of suicide in children and adults.

Millions of Americans use antidepressants, which include Wyeth's Effexor, Pfizer Inc.'s Zoloft, GlaxoSmithKline Plc's

Paxil, Eli Lilly and Co's Prozac and Forest Laboratories Lexapro.